The invention refers to diagnosis and therapy of muscle degenerative disorders, as Duchcnnc Muscular Dystrophy (DMD by means of a class of specific miRNAs. In particular the invention refers to a method for the diagnosis of a muscle disorder and damage leading to muscle fiber degeneration, inflammation and fibrosis or for monitoring the progress of therapeutic treatments on subjects affected by said disorder consisting in detecting in a biological sample at least two of dystromiR molecules, each of the two dystromiR molecules belonging to one of the following groups: a) muscle regeneration (miR-206, miR-34), b) muscle differentiation (mix-1, miR-133), c) inflammatory (miR-223, miR-21) and d) tissue integrity (miR-29, miR-30).
miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics